ABEO Stock — Abeona Therapeutics Inc

Abeona Therapeutics Inc (ABEO)

Updated October 16, 2026.

ABEO is a Stock. Total return is -100.0% over the past 41.9 years.

Abeona Therapeutics is a commercial-stage biopharmaceutical company developing gene and cell therapies for rare genetic diseases, including ZEVASKYN for recessive dystrophic epidermolysis bullosa and pipeline programs targeting conditions such as X-linked retinoschisis, Stargardt disease, and autosomal dominant optic atrophy. The company does not currently distribute to shareholders. This security appeals to investors seeking exposure to early-stage biotech innovation, though it carries the risks typical of development-stage pharmaceutical companies without approved revenue-generating products.

ABEO performance

Price and return data through 2026-10-16.

Total return is -100.0% over the past 41.9 years. Over the past year its total return — price change plus distributions reinvested — is -19.0%. Its deepest 1-year drawdown was 41.6%.

ABEO key facts

Asset type

Stock

Asset class

Equity

Inception date

11/05/1984

Distribution frequency

None

Last close

$4.43 (as of 2026-10-16)

Market cap

$253,325,195

Average volume

819503.0

Ex-dividend date

03/31/2000

Beta

1.3

Payout ratio

0.0%

Forward P/E

18.6567

EPS

$-1.18

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ABEO risks and drawbacks

The deepest 1-year drawdown on record here is 41.6%.

Who may consider ABEO — and who may not

It is a weaker fit for investors who need monthly cash flow (ABEO does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on ABEO

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions